|
|
 |
| |
2008 Annual Meeting Abstracts
Fesoterodine Significantly Improves Treatment Response Rates in Subjects With Overactive Bladder as Early as 2 Weeks: Subpopulation Analyses of 2 Phase III Trials
David Staskin1, Victor Nitti2, Tamara Bavendam*3, Joseph T. Wang*3, Jeffrey Trocio*3
1New York Presbyterian Hospital, New York, NY;2New York University Medical Center, New York, NY;3Pfizer Inc, New York, NY
Introduction: This was a post hoc subanalysis of pooled data from 2 double-blind, placebo (PBO)-controlled trials in subjects with overactive bladder.
Materials & Methods: Eligible subjects were randomized to PBO, fesoterodine (FESO) 4 mg, or FESO 8 mg for 12 weeks. Patient-reported Treatment Response rates, defined as responses of “improved” or “greatly improved” on the 4-point Treatment Benefit Scale, were analyzed using asymptotic normal approximation methodology.
Results: Treatment Response rates were significantly higher in all subgroups treated with FESO 4 (n=532) or 8 mg (n=543) compared with PBO (n=545) at weeks 2 and 12, except for men receiving FESO 4 mg at week 2 (Table). FESO 8 mg was significantly more effective than FESO 4 mg among incontinent subjects and all subjects combined at weeks 2 and 12 and among women and subjects aged ≥65 years at week 12.
Conclusions: The percentage of subjects reporting a positive Treatment Response was significantly higher in the FESO 4 and 8 mg groups vs PBO at 2 weeks and sustained through the end of treatment. In several subgroups, Treatment Response rates were significantly higher among subjects who received FESO 8 mg compared with those who received FESO 4 mg. 
|
|
| |
|
|
| |
|
|
|
|
